GARG PUSHKAL (CMO & EVP Dev & Med Affairs) sold 20.1% of their position (4.71K shares) of ALNYLAM PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $1.52M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−106.00
Price / share
$319.03
Trade value
$33.82K
% of position
Common Stock
Shares
−102.00
Price / share
$320.01
Trade value
$32.64K
% of position
Common Stock
Shares
−215.00
Price / share
$320.81
Trade value
$68.97K
% of position
Common Stock
Shares
−289.00
Price / share
$321.82
Trade value
$93.01K
% of position
Common Stock
Shares
−350.00
Price / share
$323.01
Trade value
$113.05K
% of position
Common Stock
Shares
−767.00
Price / share
$323.84
Trade value
$248.39K
% of position
Common Stock
Shares
−272.00
Price / share
$324.88
Trade value
$88.37K
% of position
Common Stock
Shares
−208.00
Price / share
$325.67
Trade value
$67.74K
% of position
Common Stock
Shares
−654.00
Price / share
$322.33
Trade value
$210.80K
% of position
Common Stock
Shares
−740.00
Price / share
$323.55
Trade value
$239.43K
% of position
Common Stock
Shares
−510.00
Price / share
$324.59
Trade value
$165.54K
% of position
Common Stock
Shares
−500.00
Price / share
$326.08
Trade value
$163.04K
% of position
Net shares
−4.71K
Net value
-$1.52M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/4/2026 | S · Sale | −106.00 | $319.03 | $33.82K | 0.5% | 23.41K | 23.30K |
| Common Stock Direct | 3/4/2026 | S · Sale | −102.00 | $320.01 | $32.64K | 0.4% | 23.30K | 23.20K |
| Common Stock Direct | 3/4/2026 | S · Sale | −215.00 | $320.81 | $68.97K | 0.9% | 23.20K | 22.98K |
| Common Stock Direct | 3/4/2026 | S · Sale | −289.00 | $321.82 | $93.01K | 1.3% | 22.98K | 22.69K |
| Common Stock Direct | 3/4/2026 | S · Sale | −350.00 | $323.01 | $113.05K | 1.5% | 22.69K | 22.34K |
| Common Stock Direct | 3/4/2026 | S · Sale | −767.00 | $323.84 | $248.39K | 3.4% | 22.34K | 21.58K |
| Common Stock Direct | 3/4/2026 | S · Sale | −272.00 | $324.88 | $88.37K | 1.3% | 21.58K | 21.30K |
| Common Stock Direct | 3/4/2026 | S · Sale | −208.00 | $325.67 | $67.74K | 1.0% | 21.30K | 21.10K |
| Common Stock Direct | 3/5/2026 | S · Sale | −654.00 | $322.33 | $210.80K | 3.1% | 21.10K | 20.44K |
| Common Stock Direct | 3/5/2026 | S · Sale | −740.00 | $323.55 | $239.43K | 3.6% | 20.44K | 19.70K |
| Common Stock Direct | 3/5/2026 | S · Sale | −510.00 | $324.59 | $165.54K | 2.6% | 19.70K | 19.19K |
| Common Stock Direct | 3/5/2026 | S · Sale | −500.00 | $326.08 | $163.04K | 2.6% | 19.19K | 18.69K |
| Total | −4.71K | -$1.52M | ||||||
Common Stock
IndirectCommon Stock
Indirect| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 250.00 | Indirect |
| Common Stock | 431.00 | Indirect |
| Total | 681.00 | 681.00 indirect |